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Abstract: Adamantiades-Behçet’s disease (ABD) is a multisystemic vasculitic disease. 
It is most prevalent in the Eastern Mediterranean countries and the Eastern region of 
Asia. Its effect on the eye can range from mild to debilitating, resulting in total blindness. 
A necrotizing and obliterative vasculitis affects both arteries and veins of organs. Recurrent 
attacks of uveitis, oral aphthous ulcers, skin lesions, and genital ulcers are common. Topical 
and systemic corticosteroids have been the mainstay in the treatment of ocular inflamma-
tion for many years; however, due to the several known side effects of corticosteroids and 
thanks to scientific advances, more novel approaches to ABD treatment have been emerging. 
Antimetabolites such as methotrexate and azathioprine have been utilized with the latter 
showing positive results. Chlorambucil has been utilized effectively for ocular manifestations 
of ABD. Interferon alpha has shown encouraging results in the management of refractory 
ocular inflammation associated with ABD, either alone or in combination with other immu-
nosuppressive agents. Surgical interventions to deal with complications from ABD can be 
safely done if adequate control of inflammation is achieved peri-operatively. Early detection 
and aggressive treatment, when needed, have proven to be essential in the management of 
this relentlessly explosive disease.
Keywords: Adamantiades-Behçet’s disease, Behçet’s disease, ocular inflammation, uveitis, 
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Introduction
Historical context
Adamantiades-Behçet’s disease (ABD) is a chronic, relapsing systemic vasculitis 
that afflicts organs encompassing the eye, skin, gastrointestinal tract, joints, genitalia, 
and central nervous system. To date, a clear etiology of the disease has not been 
identified. Described possibly by Hippocrates in the 5th century BC,1 it is named 
after Benedictos Adamantiades, a Greek ophthalmologist, and Hulusi Behçet, 
a Turkish dermatologist, who in the 1930s separately published on their patients 
with the findings of recurrent iritis as well as oral and genital ulcers. Although 
Adamantiades had presented his case report2 seven years prior to Behçet, the 
disease is widely referred to as Behçet’s disease primarily due to the popularity of 
the German medical literature in which the latter presented his case series of three 
patients.3 To properly reflect the importance of the contribution both of these physi-
cians made to the recognition of this devastating disease, this article will adopt the 
name Adamantiades-Behçet’s disease (ABD).Clinical Ophthalmology 2009:3 568
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epidemiology
ABD is most commonly found in countries of the Eastern 
Mediterranean and the Eastern edge of Asia. Its predominant 
distribution between the 30° and 45° north latitudes roughly 
correspond to the old Silk Road utilized for trades between 
the East and Europe.4 While its prevalence is much higher in 
countries such as Turkey, Iran, and Japan, ABD accounts for 
only 0.2% to 0.4% of uveitis cases in the United States, with 
a prevalence of 4 patients per 1 million population.5,6
Earlier reports from Asia and the Mediterranean basin 
showed a male preponderance of ABD;5,7,8 however, more 
recent reports suggest a more equal distribution between 
sexes. It appears that the complete type of ABD (see Clinical 
features below) is more common in males, while the incom-
plete type has a 1:1 male-to-female ratio. ABD has been 
reported in all ages, but mostly between 25 and 35 years. 
In general, younger age and male gender are associated with 
more disease severity.
Genetics
Due to the increased prevalence in certain racial groups, it is 
clear that genetics plays an important role in the pathogenesis 
of ABD. HLA-B5 (and its subtype HLA-B51), HLA-B12, 
HLA-B27, and HLA-A26 have all been implicated in 
ABD;9–11 of these, HLA-B5 appears to be associated with the 
worst ocular prognosis.12 On the other hand, HLA-DR1 and 
HLA-DQw1 seem to confer resistance to the disease.13
Pathology and immunology
The pathology of ABD varies depending on the location of 
the lesions, but its principal features include perivascular infil-
trates of lymphocytes and mononuclear cells, and swelling, 
proliferation and subsequent fibrinoid necrosis of small 
blood vessels, especially venules. Excessive number of mast 
cells may be found in the recurrent mucocutaneous ulcers.14 
Demyelination is the most common finding in the brain.15
Ocularly, acute uveitis is characterized by diffuse 
infiltration of neutrophils, followed by lymphocytes, 
monocytes and mast cells in the iris, ciliary body and 
choroid. When the disease becomes chronic and recurrent, 
the presence of increased collagen can lead to iris atrophy, 
posterior synechiae, cyclitic membrane formation, and 
choroidal thickening. Retinal vasculitis, which involves 
veins more than arteries, is typified by significant infiltration 
of leukocytes and plasma cells in and around blood vessels 
and deeper into the retinal tissue. Although retinal pigment 
epithelium destruction is minimal, the photoreceptor layers 
are often damaged. In more advanced vasculitis, fibrosis 
of the vessels can lead to the obliteration of the vascular 
structures. In addition, the vasculitic process may result in 
optic neuritis, ischemia, and even atrophy.
The T lymphocyte is the predominant cell type in the immu-
nopathogenesis of ABD. The early lesions in ABD resemble 
a delayed-type hypersensitivity reaction (type IV), while the 
late lesions correspond to an immune-complex type reaction 
(type III). Whether vessel inflammation is driven by immune 
complexes is debatable, however, as immunoglobulins are not 
typically found in the vessel walls of ABD patients.
Clinical features
The diagnosis of ABD is based on clinical findings. Two 
separate diagnostic systems currently exist: one by Behçet’s 
Research Committee of Japan in 1974 (Table 1),16 and the other 
by the International Study Group for Behçet’s Disease in 1990 
(Table 2).17 The major difference between the two systems 
is that the former emphasizes ocular symptoms, while the 
latter stresses the importance of oral aphthae (thus, we prefer 
the Japanese system in our care of ophthalmic patients).
Systemic manifestations
Oral aphthous ulcer is the most common finding in ABD. These 
lesions of 3 to 15mm diameter are recurrent and very painful. 
The lesions can be found anywhere in the oral cavity, including 
the lips, gums, tongue, palate, uvula, and posterior pharynx. 
Table 1 Diagnostic criteria of Adamantiades-Behçet’s disease 
(ABD) suggested by Behçet’s research Committee of Japan
Major criteria
  recurrent oral aphthous ulcers
  recurrent genital ulcers




  Gastrointestinal tract ulceration
  epididymitis
  vasculitis/vasculopathy
  Neuropsychiatric symptoms and signs
ABD types
  Complete (4 major)
  Incomplete (3 major, or ocular inflammation with 1 other major)
  Suspect (2 major, no ocular inflammation)
  Possible (1 major)
Modified from Newman NM, Hoyt WF, Spencer WH. Macula-sparing monocular 
blackouts: Clinical and pathologic investigation of intermittent choroidal 
vascular insufficiency in a case of periarteritis nodosa. Arch Ophthalmol. 1974; 
91(5):367–370.134Clinical Ophthalmology 2009:3 569
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They typically last 7 to 10 days and resolve spontaneously, 
though some patients never fully recover before the next bout 
of ulcers appears. Skin eruptions resembling acne vulgaris 
or folliculitis are common cutaneous findings, especially 
above the neck. Erythema nodosum can be found not only on 
the tibia (as classically seen in sarcoidosis), but also on the 
face, neck, and buttock. Genital ulcers are another common 
mucocutaneous finding of ABD. They can occur on the penis, 
scrotum, vulva, and vaginal mucosa; at times, they are located 
in the perianal areas. Although epididymitis is common in 
ABD, urethritis is not a known feature, which may be helpful 
in differentiating the condition from reactive arthritis. Further-
more, superficial thrombophlebitis can occur on both upper and 
lower extremities, and these lesions should be evaluated very 
carefully as they may indicate a more widespread disease.
Neurologic involvement (neuro-ABD) is one of the most 
serious complications of ABD. The reported frequency of 
CNS involvement in ABD ranges from 3% to 10%.8 Its 
manifestations are wide-ranging and nonspecific: migraine-
like headaches, stiff neck, cranial nerve palsies, hemiparesis, 
cerebellar ataxia, pyramidal and extrapyramidal signs, 
seizures, peripheral neuropathies, mental status change, audio-
vestibular deficits, and many more have all been reported.
Arthritis occurs at some point in approximately half 
of  ABD patients, with lower extremity joints most commonly 
affected. It can be monoarticular, oligoarticular, or polyarticu-
lar, but it is typically not chronic or destructive. Other systemic 
features of ABD have been documented in the cardiovascular, 
pulmonary, gastrointestinal, and renal systems.
Ocular manifestations
Ocular symptoms occur in 43%18 to 72%19 of ABD patients 
and affect males more commonly than females. They are 
not usually the first presenting manifestations of ABD 
(only in about 10 to 13% of the cases).20,21 The time between 
oral and genital lesions and eye involvement is estimated to 
be 3 to 4 years.22 Although the ocular disease may initially 
be unilateral, it almost always progresses to both eyes.
Anterior uveitis of ABD is nongranulomatous. It is 
explosive in nature but may resolve in 2 to 3 weeks without 
any therapy. The presenting symptoms and signs include 
periorbital pain, blurry vision, conjunctival injection, ciliary 
flush, anterior chamber cells and flare, and fine keratic 
precipitates. Mobile hypopyon, which moves as a patient 
changes head positions, is a classic finding, although it is 
exceedingly rare today likely due to earlier diagnosis and 
treatment; Tugal-Tutkun et al found hypopyon in only 12% 
of 1567 eyes.27 At times, the hypopyon is not immediately 
visible but may be discovered in the angle via gonioscopy 
(termed angle hypopyon). Of note, hypopyon is also found in 
HLA-B27-associated anterior uveitis; however, it is usually 
less mobile than that found in ABD. Repeated attacks in the 
anterior chamber result in structural damages such as anterior 
and posterior synechiae and iris atrophy. Furthermore, in the 
case of chronic posterior segment inflammation, rubeosis may 
become apparent and signify a poor ocular prognosis.
In the posterior segment, vitreal inflammatory cells are 
always present during acute attacks. Chronic inflammation of 
the vitreous frequently leads to posterior vitreous detachment. 
The most prominent retinal change is obliterative, necrotizing 
vasculitis that afflicts both arteries and veins; evident on the 
fundoscopic exam are engorged veins, perivascular sheath-
ing (veins usually before arteries), intraretinal and vitreous 
hemorrhage, macular edema, retinal ischemia and infarct, 
disc swelling, and chorioretinal scarring. Repeat vasculitic 
attacks ultimately result in permanent vascular occlusion 
(central or branch retinal vein or artery occlusion) and 
tissue hypoxia, which induces neovascularization of the 
optic nerve (neovascularization of the disc, or NVD) or else-
where (NVE). When only posterior segment inflammation 
is present, the patient typically relates painless decrease in 
vision with a sudden increase in floaters.
As with most chronic intraocular inflammation, ABD 
uveitis is complicated by cataracts and glaucoma, both of 
which result from the inflammation itself and the chronic 
corticosteroid therapy that is all too often employed in the 
patients. Clearly, the ocular involvements in ABD have 
extremely dire consequences, as each recurrence damages 
the eye. Therefore, it is essential for a clinician to diagnose 
the disease early and begin aggressive treatments, which 
usually comprise systemic immunomodulatory medications. 
Even as a patient’s disease enters remission, one must not be 
Table 2 Diagnostic criteria of Adamantiades-Behçet’s disease 
suggested by the international Study Group for Behçet’s disease
recurrent oral aphthous ulcers (at least 3 times a year) and 2 of the 
following:
  recurrent genital ulcers
  Skin lesions
  Ocular inflammation
  Positive pathergy test (Behçetine test)a
aPathergy test is performed by inserting a 20-guage or smaller needle (no injection) 
5 mm obliquely into the skin of the flexor aspect of the forearm.   The test is positive 
if there is an indurated erythematous papule or pustule with 2 mm diameter after 
24 to 48 hours.
Modified from Gold DH. Ocular manifestations of connective tissue (collagen) 
diseases. in:   Tasman  w,  Jaeger  Ae, editors. Duane’s Clinical Ophthalmology. Philadelphia: 
J.B. Lippincott. 1989;5:17–19.135Clinical Ophthalmology 2009:3 570
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complacent because recurrence is the rule in ABD. Regardless 
of the disease activity, patients should always have regular 
slit-lamp exams. Angiographic and electrophysiological 
studies are also useful in monitoring posterior segment 
changes and prognosticating visual outcomes.
Treatment
Corticosteroids
For many years, topical and systemic corticosteroids 
have been the gold standard in the treatment of ocular 
inflammation, contributing immensely to the treatment 
of these often difficult patients. Prolonged corticosteroid 
therapy, however, is associated with a broad spectrum of 
local and systemic side effects, such as cataracts, glaucoma, 
systemic hypertension, hyperglycemia, weight gain, peptic 
ulcers, Cushingoid syndrome, psychosis, and many, many 
others. Furthermore, it is not uncommon for ABD to become 
refractory to corticosteroids, with progressive loss of vision 
and the eventual need for additional therapeutic options.23
Systemic corticosteroids
The use of systemic corticosteroids in ABD is controversial. 
If they are to be used, they are preferred in cases of posterior 
inflammation, panuveitis, retinitis and/or severe anterior 
chamber and intermediate inflammation with multiple exac-
erbations that are poorly responsive to topical and/or peri-
ocular corticosteroids. In these cases, they should be given 
in high doses such as oral prednisolone (1 to 2 mg/kg daily) 
given in a single morning dose after breakfast and/or as an 
intravenous dose as a pulse methylprednisolone (1 g daily 
for 3 consecutive days). After disease control is attained, 
corticosteroids should be tapered gradually to a maintenance 
dosage of 15 to 20 mg daily.
Even though systemic corticosteroids have proven 
effective in the treatment of acute ocular attacks in patients 
with ABD, one should try to avoid the chronic use of these 
agents in an attempt to reduce the associated side effects. 
Furthermore, steroid-resistance can occur in patients with 
posterior segment involvement,24,25 and corticosteroids may 
be associated with retinal thrombosis.26,27
Regardless of the fact that some ophthalmologists never 
give systemic corticosteroids due to the belief of a worse 
long-term prognosis, we believe that it is appropriate to 
employ a short course of high-dose systemic corticoste-
roids to an existing regimen of immunosuppressive drugs 
in cases of acute posterior segment involvement, in an 
effort to eradicate all inflammation while waiting for other 
medications to take full effects.
Topical corticosteroids
The use of topical corticosteroids is usually applied to mild 
episodes of anterior and intermediate inflammation. These 
agents may be given as drops during the day and ointment at 
bedtime. The use of the so-called stronger corticosteroids such 
as prednisolone 1% and/or dexamethasone is preferred over 
weaker ones such as fluorometholone. Regardless of the route 
of administration, topical corticosteroids should be given at a 
large dose initially and then tapered as soon as the inflamma-
tion is brought under control, possibly over a period of several 
weeks once the inflammation is controlled. It is not uncommon 
that after the corticosteroids are withdrawn the inflammation 
may recur. At the Massachusetts Eye Research and Surgery 
Institution, if the inflammation is mild, we usually start therapy 
with one drop 4 times a day. We increase the frequency in more 
severe cases. These drops are then gradually tapered 1 drop 
every week once the inflammation is controlled.
Once the inflammation is suppressed and the therapy has 
been discontinued, it is prudent to follow the patient to ensure 
the absence of recurrence. It is not uncommon that the inflam-
mation recurs upon tapering of corticosteroids. To monitor 
the anterior chamber inflammatory status, one should use 
the classification put forth by the Standardization of Uveitis 
Nomenclature (SUN) Working Group.28 In our practice we 
do not chase every single cell; we treat inflammatory cell 
reaction equal or greater than 1+.
Periocular corticosteroids
This route of administration is offered to patients with more 
severe inflammation, especially with posterior uveitis, vitritis 
and macular edema. Several studies have demonstrated the 
benefit of periocular corticosteroid injections in the treatment 
of uveitic macular edema.29–32 We believe that periocular 
corticosteroids may be especially beneficial in patients with 
unilateral disease, to whom they could be administered alone 
or in combination with systemic corticosteroid and/or a steroid-
sparing agent. Periocular corticosteroids may also be offered 
to severe anterior chamber inflammation with poor response 
to topical corticosteroids. Depot agents such as triamcinolone 
acetonide are preferred over other types of corticosteroids such 
as prednisolone and dexamethasone, as they are able to achieve 
a longer lasting anti-inflammatory effect.
Azathioprine
Azathioprine (AZA) is an imidazolyl derivative of 
6-mercaptopurine. It is metabolized to 6-mercaptopurine, and 
then to thioinosine-5-phosphate, which is a purine analogue. 
The latter interferes with DNA, RNA, and protein synthesis Clinical Ophthalmology 2009:3 571
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by acting as a false precursor for adenine and guanine 
synthesis. Azathioprine also acts by suppressing circulating 
T-cells, selectively decreasing monocyte precursors, sup-
pressing delayed hypersensitivity reactions, and inhibiting 
T-lymphocyte function.33
Kötter and associates evaluated the efficacy of different 
treatment strategies in controlling the several organ manifes-
tations of ABD.34 The results revealed that in patients with 
uveitis (posterior or panuveitis), AZA was successfully used 
to achieve complete remission in 8 of 10 cases when combined 
with CSA and corticosteroids. Hamuryudan and colleagues 
conducted a two-year randomized, placebo-controlled, 
double-blind trial studying the effect of AZA therapy 
on long-term prognosis in ABD.35 The authors followed 
73 ABD patients, 48 of whom had ocular involvement and 
25 who did not. It was found that AZA was superior to 
placebo in preventing eye diseases in patients without ocular 
involvement. In addition, a decrease in hypopyon uveitis 
episodes was observed in patients with ocular involvement. 
Other studies have also found that early AZA treatment was 
effective in improving the long-term visual prognosis of ABD 
patients and preventing new ocular involvement.36–38 A study 
by our group showed more equivocal results.38 We found that 
only 3 of 8 patients achieved control of ocular inflammation 
in combination with cyclosporine or systemic corticosteroids. 
As such, we do not consider azathioprine to be the most 
effective drug for the treatment of ABD.
The most common side effect of AZA is gastrointestinal 
upset. Myelosuppression is a serious side effect, and is 
reversible and dose-related. Liver enzyme abnormalities are 
observed in less than 2% of patients.33
Methotrexate
Methotrexate was first used in 1958 to treat leukemia. It is a 
folic acid analogue that competitively binds and inactivates 
the enzyme dihydrofolate reductase (DHFR) which plays a 
key role in converting dietary folic acid to reduced, meta-
bolically active folates (dihydrofolate and tetrahydrofolate). 
Folate plays a role in the metabolism of histidine, thymidylate 
and purine synthesis, and in the conversion of homocysteine 
to methionine. This along with its antiangiogenic properties, 
cellular and humoral immunosuppression, and inhibition of 
cytokine production may account for the therapeutic effect 
of low-dose methotrexate.33,39
The bioavailability of methotrexate is 100% when 
given intravenously. It also exhibits a high bioavailability 
when given in low doses orally, intramuscularly, and sub-
cutaneously. Metabolism takes place in the liver and all 
the metabolites are cleared renally.33 Folinic acid is used to 
protect or shield normal cells from the toxic effect of metho-
trexate when used in high doses. Folinic acid remains active 
without the need for reduction by DHFR. It functions by 
restoring thymidylate, methionine, and purine biosynthesis. 
The activity of folinic acid is impervious to the presence of 
methotrexate in the system.39
Methotrexate has been used in treating a large number 
of ocular inflammatory diseases. The evidence regarding 
methotrexate use in ABD uveitis is scant. It has been shown 
that methotrexate is not entirely effective for posterior uveitis, 
but it is more potent for anterior uveitis when used at a low 
dose of 7.5 to 25 mg weekly.40–42
Methotrexate is mostly well-tolerated and side effects 
improve with reducing dosage. The most common side effects 
are nausea, vomiting, diarrhea, anorexia, and weight loss. 
Cutaneous vasculitis, urticaria, alopecia, photosensitivity, 
and cutaneous nodules are also side effects of low-dose 
methotrexate.43 Hepatotoxicity is a likely side effect and 
alcohol consumption should be avoided by patients in treat-
ment with methotrexate. Duration of therapy and age are 
risk factors for hepatotoxicity, and abnormal liver enzymes 
are seen in 15% of patients.44,45 A study by our group on the 
long-term risk of malignancy among patients treated with 
immunosuppressive agents for ocular inflammation showed 
that methotrexate has virtually no long-term carcinogenic 
effects.46 Pregnant women are not eligible for methotrexate 
treatment as it is a definite teratogen.33
Colchicine
Colchicine is an anti-inflammatory plant alkaloid and is 
well-known in the treatment of gout.47 It acts by inhibiting 
neutrophil chemotaxis by binding to microtubular proteins 
and interfering with the function of the mitotic spindle.48–50 
Consequently, the migration of granulocytes, which are 
responsible for the release of lactic acid and inflammatory 
enzymes to inflammation sites, is inhibited. Through the 
prevention of spindle formation, it appears that colchicine 
can also act as an antimitotic agent, stopping cell division 
in metaphase.
Colchicine is effective in the treatment of ocular 
manifestations of ABD, both alone or in combination 
with other drugs.51–55 One earlier study showed that 
104 of 131 patients with ABD were responsive to colchicine 
therapy.54 Colchicine has been successful in the treatment of 
anterior uveitis at a dosage of 1 mg daily; however its effi-
cacy in severe posterior uveitis is yet to be determined.56,57 
Masuda and associates reported that colchicine was inferior Clinical Ophthalmology 2009:3 572
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to cyclosporine in treating the ocular manifestations of ABD, 
in addition to oral skin lesions, aphthous ulcer, and genital 
lesions.58 Nonetheless, colchicine and cyclosporine may 
be used in combination.59
Colchicine is usually well tolerated in moderate doses, 
gastrointestinal side effects being the most common. Nephro-
toxicity, hemorrhagic gastroenteritis, ascending paralysis of 
the central nervous system, vascular damage, and muscular 
depression may be caused by acute toxicity, while azosper-
mia, myopathy, aplastic anemia, and agranulocytosis may 
occur in chronic use.60
Chlorambucil
Chlorambucil, a nitrogen mustard derivative, is widely used 
in the treatment of lymphomas. It acts by alkylating purine 
bases. This causes DNA strands to undergo intrastrand 
crosslinking as well as DNA-to-protein crosslinking, which 
disrupts DNA replication, transcription, and nucleic acid 
function, ultimately leading to apoptosis.33 Chlorambucil 
has a high absorption in the gut, reaching peak concentration 
within one to two hours.61 Phenylacetic acid mustard, the 
active metabolite, is produced in the liver, and is hydrolyzed 
into an inactive compound, along with chlorambucil, and 
excreted renally. The half-life of phenyl acetic mustard is 
145 minutes and that of chlorambucil is 92 minutes.
Two approaches exist for the use of chlorambucil in 
uveitic patients. The first, described as the traditional method, 
consists of administering 0.1 to 0.2 mg/kg body weight of the 
medication daily. Treatment would continue for 1 year after 
the disease has been controlled so as to achieve “long-term, 
drug-free remission.”62 The second approach consists of 
administering short-term, high dose therapy. One would begin 
at 2 mg daily for 1 week and increase the dosage by 2 mg daily 
each week thereafter. The increase in dosage would continue 
either until inflammation is controlled or a white blood count 
of below 2,400 cells per microliter or a platelet count below 
100,000 cells per microliter is achieved. This treatment would 
typically be carried out for 3 to 6 months but discontinued 
immediately in case of bone marrow toxicity.63
A study by Mudun and coworkers evaluated the 
responsiveness of patients with ABD uveitis to short-term 
chlorambucil therapy.64 The study population consisted of 
44 patients and efficacy of chlorambucil was evaluated by 
measuring the frequency of disease flare-ups per year and 
the longest time period between flare-ups while in treatment. 
The results revealed that the mean frequency of attacks had 
decreased from 4.9 ± 2.3 to 0.9 ± 1.4 (P  0.0001) and the 
mean longest period between the attacks was prolonged 
from 4.4 ± 2.3 months to 25.7 ± 23.1 months (P  0.0001). 
Goldstein and associates studied 53 patients with uveitis 
treated with short-term high-dose chlorambucil.65 The 
treatment period ranged from 2 to 9 months. Seventeen 
patients out of the total population had ABD-associated 
uveitis. Thirteen of those patients (76%) achieved sustained 
remission after initial treatment. Our group conducted a 
noncomparartive case series on 28 patients with chronic 
noninfectious uveitis treated with chlorambucil.66 Of those 
patients, 7 were diagnosed with ABD. Results showed that all 
7 patients responded to treatment; however, only 2 of 7 had 
an ocular and systemic response. Two of 7 patients responded 
both ocularly and systemically but later relapsed. Three of 
7 patients showed an ocular response but failed to respond 
systemically. The study demonstrated that chlorambucil is a 
safe treatment when administered and monitored expertly.
Bone marrow depression is a serious side effect of 
chlorambucil therapy. However, this can be reversed by 
reducing the dosage or discontinuing the treatment. Sterility 
is another major concern related to chlorambucil therapy. 
Men are seemingly more susceptible to sterility than women. 
A relationship has been described between cumulative 
dose of therapy and gonadal effect of chlorambucil.66 It has 
been shown that doses less than 8.2 mg/kg in children and 
6.1 mg/kg in adults do not affect fertility.67–70 With the option 
of sperm cryopreservation now readily available, we believe 
that sterility is a risk worth taking in the quest to prevent 
blindness in ABD patients.
Cyclophosphamide
Cyclophosphamide is a nitrogen mustard derivative similar 
to chlorambucil. It is designed to target neoplastic cells more 
selectively than healthy cells. Phosphoramide mustard is the 
active compound which inhibits DNA and RNA synthesis 
and results in apoptosis. Cyclophosphamide acts on both 
primary and established cellular and humoral immune 
responses, suppressing delayed-type hypersensitivity, mixed 
lymphocyte reactions, mitogen-induced and antigen-induced 
blastogenesis, and production of cytokines.39 The drug is 
primarily excreted renally with less than 25% remaining 
chemically unaltered in the urine.71,72 The drug can be admin-
istered both orally and intravenously and is well tolerated in the 
gut. Nonetheless, we prefer the intravenous method for ease 
of saline flushing and shorter time of exposure in the body.
Not much evidence exists regarding the effectiveness of 
cyclophosphamide in ABD-associated ocular inflammatory 
disease, especially as a monotherapy. We usually select chlo-
rambucil over cyclophosphamide for the treatment of ABD Clinical Ophthalmology 2009:3 573
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ocular disease, unless urgent care is required, in which case 
we employ intravenous cyclophosphamide. As with chlo-
rambucil, cyclophosphamide can result in serious adverse 
effects if not dosed and monitored expertly.
Thalidomide
Thalidomide is a derivative of glutamic acid and was synthe-
sized in the 1950s. It was originally used as an antihistamine and 
anticonvulsant, and subsequently a sedative and anti-emetic. 
Tragically, it was later discovered that thalidomide was highly 
teratogenic and was linked to thousands of birth defects world-
wide. This resulted in the drug being pulled off the market, 
and it did not gain FDA approval until nearly 40 years later.73
Thalidomide is reported to have an immunomodulatory, 
anti-inflammatory, and anti-angiogenic effect. The proposed 
mechanism of its immunomodulatory/anti-inflammatory 
action is that thalidomide selectively inhibits the production 
of tumor necrosis factor-alpha (TNF-α) in monocytes by the 
accelerated degradation of TNF-α mRNA and the reduction 
of its half-life. In addition, the drug also results in the decrease 
of neutrophil migration to the site of inflammation and the 
reduction of polymorphonuclear phagocytosis. Thalidomide 
also co-stimulates the production of T-lymphocytes and, 
as such, proves useful in lowering TNF-α levels while 
maintaining normal immunity.59,74
Thalidomide’s anti-angiogenic activity has been 
demonstrated in solid tumors, in the control of gastric bleed-
ing and rabbit-model corneal neovascularization. When 
thalidomide was studied in a mouse-model retinopathy of 
prematurity-associated neovascularization and retinopathy, 
it was not effective.74–79
In treating ABD, thalidomide appears to have favorable 
results in orogenital lesions, arthritis, and erythema nodosum. 
The results in uveitis are not as encouraging.80–82 In 1986, 
Hamza studied the use of thalidomide in 30 male patients 
with ABD.83 Twenty-six of 27 patients with oral ulcerations 
showed improvement with therapy. Four patients with 
erythema nodosum had resolution of the lesions within 7 to 
10 days after thalidomide was initiated; once the medication 
was purposely withdrawn, all 4 patients flared up within a 
week. Sixteen patients had uveitis, and the disease was active 
in 11 patients at the time the treatment was initiated. Three 
patients with uveitis had total regression of inflammation 
within 1 to 3 months. In 4 patients inflammation was stable; 
it did not improve or worsen. Four patients experienced a dete-
rioration of their uveitis requiring the use of corticosteroids.
The most notorious side effect of thalidomide is 
teratogenecity, with phacomelia being the best recognized 
congenital abnormality. There have also been reports of 
neural tube abnormalities, micro-ophthalmia, duodenal 
stenosis, and mid-line hemangiomas.84 Peripheral neu-
ropathy is another serious side effect resulting in painful, 
symmetrical paresthesias of upper and lower extremities as 
well as sensory loss.85
Tacrolimus
Tacrolimus, also known as FK506, is a macrolide analogous 
to cyclosporin A. It is a calcineurin inhibitor isolated from 
the fungus Streptomyces tsukubaensis and is frequently used 
in organ transplantation. Like cyclosporine, it binds to the 
intracellular FK-binding protein and then associates with 
calcineurin. This ultimately leads to the inhibition of TNF-α 
and GM-CSF production.33,59,86
Tacrolimus is poorly absorbed orally. Its absorption 
form the gastrointestinal tract is incomplete, variable, and 
limited when taken with food. It is metabolized hepatically 
via the cytochrome P450 system, and fecal elimination 
accounts for over 90% of elimination.33,39 The drug may also 
be given intravenously, but most uveitis patients receive it 
orally. The initial dosage for uveitis recommended by an 
expert panel is 0.05 mg/kg daily with a maximum dosage 
of 0.3 mg/kg daily.
Tacrolimus has been used to treat ABD-associated uveitis 
in patients who have failed cyclosporine.87–89 Sloper and 
colleagues have studied the efficacy of tacrolimus in patients 
who did not respond to cyclosporine treatment.90 Six patients 
with posterior uveitis – 3 associated with ABD – refractory 
to cyclosporine were treated with tacrolimus. The 3 patients 
with ABD as well as 2 other patients (1 with microscopic 
polyangiitis and 1 with pars planitis) showed improvement 
in uveitis with the therapy. Hogan and associates recently 
studied tacrolimus treatment in 62 patients with noninfectious 
uveitis.91 It was found that the drug’s efficacy was sustained on 
a long-term basis with an excellent cardiovascular risk profile.
The side effects of tacrolimus are similar to those of 
CSA in terms of gastrointestinal disturbance, hypertension, 
neurotoxicity, and nephrotoxicity. It differs from CSA in that 
it is diabetogenic. In addition, the degrees of hypertrichosis, 
hyperlipidemia, gingival hypertrophy and coarsening of the 
features are less with tacrolimus.59
interferon-alpha
Interferon-alpha (IFN-α) is a cytokine initially produced for its 
antiviral properties. It was the first cytokine to be produced in 
the recombinant form. Since its production, it has been studied 
for multiple sclerosis and ABD due to its immunomodulatory Clinical Ophthalmology 2009:3 574
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capabilities. IFN-α and IFN-β are both type I interferons. 
IFN-α is produced by leukocytes and IFN-β is produced 
by fibroblasts, and they are both functionally similar. They 
modulate the production of antibodies and inhibit lymphocyte 
proliferation as well as delayed-type hypersensitivity, all the 
while enhancing T-cell and NK-cell cytotoxicity. The drug 
undergoes complete filtration in the kidneys.33,92 IFN-α2a and 
IFN-α2b are commercially available as injections.
Studies on IFN-α have shown encouraging results, especially 
in the treatment of refractory ocular inflammation associ-
ated with ABD. In addition, IFN-α has also proven effective 
when combined with other immunomodulatory agents and 
corticosteroids.59,93 Tugal-Tutkun and associates studied 44 
Turkish patients who were treated with IFN-α2a.94 The initial 
doses were 6 MU daily in 37 patients and 3 MU daily in 7 
patients, which were subsequently tapered upon suppression 
of ocular inflammation. Oral corticosteroids were either dis-
continued or kept below 10 mg daily. The authors reported 
that 16 patients (36.4%) remained free of inflammation during 
treatment, while 28 patients (63.6%) had recurrent flare ups. 
Overall, 91% of patients experienced a partial or complete 
response. Gueudry and coworkers studied 32 patients with sight-
threatening uveitis associated with ABD who failed previous 
immunosuppressive and corticosteroid therapy.95 The patients 
were treated with 3MU 3 times per week. Inflammation was con-
trolled in 28 patients (88%) over a mean observation period of 
70.6 months. The authors concluded that while the treatment was 
efficient and safe in the treatment of ABD uveitis, it appeared 
to be a suspensive therapeutic strategy as relapse occurrence 
increased following discontinuation of IFN-α; nevertheless, 
weaning of the drug was possible in some patients.
Infliximab
It has been found that TNF-α, a proinflammatory cytokine, 
is present in the sera of patients with active ABD due to 
overproduction by elevated numbers of T lymphocytes and 
monocytes.96–98 In addition, TNF receptors were also found to 
be elevated in the peripheral blood of ABD patients.97 Infliximab 
(Remicade®; Centocor Ortho Biotech Inc.) is a human – murine 
chimeric TNF-α inhibitor. An IgG monoclonal antibody, 
it binds to and deactivates TNF-α molecules. An expert panel 
has put forth the following criteria for the selection of patients 
eligible for anti-TNF-α therapy: (i) a definite diagnosis 
of ABD; (ii) presence of active disease, including objective 
signs of inflammation; (iii) previous failure of drugs that have 
a documented efficacy in controlling ABD manifestations, 
combined or not, with low dose corticosteroids (7.5 mg 
daily); (iv) presence of contraindications or intolerance to 
conventional immunomodulatory regimens; (v) absence of 
contraindications to anti-TNF treatment.99 Several studies 
have demonstrated the efficacy of infliximab therapy in the 
control of ocular and systemic manifestations of ABD.100–102 
In a prospective open study, Sfikakis and associates demon-
strated an effective remission of acute ocular inflammation 
following a single infusion of 5 mg/kg intravenous infliximab 
in 96% of patients with ocular ABD.103 The authors also 
found that cystoid macular edema resolved after 28 days 
of therapy in 90% of patients. More recently, Niccoli and 
associates conducted a prospective 24-month follow-up study 
on 12 consecutive patients with ABD-associated posterior 
uveitis refractory to other immunomodulatory therapies.104 
Patients were treated with prednisolone 1 mg/kg daily with 
rapid tapering and 9 infliximab infusions (5 mg/kg) for 
12 months. At the 12-month visit, 75% of patients achieved 
complete steroid-free disease remission with no relapses by 
week 22. At the 24-month visit, 78% of patients were still 
in remission. Tognon and coworkers studied 7 patients with 
sight-threatening relapsing uveitis refractory to previous 
therapy.105 The patients received intravenous infliximab at a 
dose of 3 to 5 mg/kg, on weeks 0, 2, 4 and then every 6 to 
8 weeks thereafter, in combination with low-dose prednisone 
and azathioprine or methotrexate. The mean follow-up period 
was 23 months, after which the total number of relapses 
dropped to 6, compared to the 21 observed in an equivalent 
period of time before treatment. Visual acuity improved 
in 4 eyes and remained stable in 9. The authors concluded 
that infliximab is safe and effective in controlling both the 
number and intensity of cases of posterior uveitis in ABD 
patients, allowing the reduction of corticosteroids and other 
immunosuppressive drugs. However, the authors remarked 
that ocular and systemic manifestations tended to recur after 
the treatment was discontinued or when the interval between 
infliximab infusions was longer than 8 weeks.
etanercept
Etanercept (Enbrel®;  Amgen/Wyeth) is a dimeric fusion protein 
consisting of the extracellular ligand-binding portion of the 
human 75 kDa (p75) TNF receptor (TNFR) linked to the Fc 
portion of human IgG1.33 Etanercept is produced by recom-
binant DNA technology. It consists of 934 amino acids and 
has an apparent molecular weight of approximately 150 kDa 
with a good tolerability when administered by subcutaneous 
injection.106
Etanercept is indicated either alone or in combination with 
other agents in the treatment of the symptoms of rheumatoid 
arthritis, polyarticular juvenile idiopathic arthritis, psoriatic Clinical Ophthalmology 2009:3 575
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arthritis and ankylosing spondylitis among others. In our 
experience, however, its effectiveness in controlling ocular 
inflammation associated with these diseases is limited. On 
the other hand, studies have shown that etanercept may be 
beneficial, at least in the short term, in maintaining visual 
acuity in patients with refractory uveitis secondary to ABD.107 
A greater response has been noted over other ABD com-
plications such as oral ulcers, nodular and papulopustular 
skin lesions as well as the arthritis symptoms, though these 
observations have been inconsistent.108,109
Other anti-TNF-α agents, such as infliximab, have shown 
better ocular results than those seen with etanercept. A recent 
study at the University of Padova, evaluated the efficacy of 
anti-TNF-α therapy, in this case infliximab, in 7 patients with 
severe ocular involvement resistant to previous treatment.110 
This therapy proved to be safe and effective in controlling 
both the number and intensity of posterior uveitis flares 
and the extraocular manifestations of ABD, but ocular and 
systemic manifestations recurred after drug withdrawal, as 
was seen in patients treated with etanercept.111
Pentoxifylline
Pentoxifylline is a methylxanthine derivative hemorheological 
agent widely known for its role in vascular disorders. 
Yasui and coworkers reported on the use of this drug on 
three male patients with ABD uveitis.112 They found that 
pentoxifylline successfully improved the patients’ clinical 
symptoms by its ability to alter cell membrane fluidity and 
membrane-receptor function, leading to decreased release 
of superoxide radicals by neutrophils. A recent study 
suggested that pentoxifylline inhibits Vgamma9/Vdelta2 
T cell function in ABD in vitro, which raises the possibility 
that this drug may be of use in dysregulated cell-mediated 
immunity immunological disorders.113
Granulocytapheresis
Still considered a novel approach to ABD, granulocytapher-
esis shows promise with its ability to reduce the neutrophil 
load from the peripheral blood through selective adsorption 
phereses. The number of studies pertaining to this treatment 
method remains scarce. There has been a report regarding the 
successful control of ABD-associated uveitis.114
Surgical interventions
Due to the nature of ABD, the use of systemic immunomodu-
latory agents alone or in combination with corticosteroids 
has become the gold standard of treatment. Nonetheless, 
ophthalmic complications such as glaucoma, macular edema, 
cataracts, neovascularization and vitreous hemorrhage are 
not uncommon in ABD patients. It is in dealing with these 
complications that surgery may play an important role in 
preventing further visual loss and even restoring useful 
vision.
Recurrent inflammation as well as prolonged use of 
corticosteroids may lead to cataract formation. Most of 
the complications observed following cataract extraction 
in ABD patients are related to poorly controlled disease 
prior to surgery. Therefore, it is advised that a patient 
receives immunosuppressive medication and prophylactic 
systemic, topical and/or periocular corticosteroids prior to the 
procedure.115 Once at least 3 months control of inflammation 
has been achieved, cataract extraction and intraocular lens 
implantation can then be safely performed. The visual out-
come depend mainly on the preoperative posterior segment 
involvement.116–118
Glaucoma, either secondary or neovascular, may be a 
significant cause of visual loss in patients with ABD. As with 
glaucoma not associated with ocular inflammatory diseases, 
initial topical hypotensive regimen should be supplemented 
with systemic therapy if better control of intraocular pres-
sure is called for. In case of poor pressure control despite 
aggressive medical treatment, surgical intervention must be 
considered. In this case, either a drainage device (we prefer 
Ahmed glaucoma valve,119 though a Molteno tube shunt is a 
reasonable option)120 or trabeculectomy with antimetabolites 
is employed.121–126
Another common complication seen in ABD patients is 
vitreous hemorrhage. ABD vasculopathy results in retinal 
hypoxia and subsequent production of vascular endothe-
lial growth factors, leading to ocular neovascularization. 
Patients with repeated episodes of hemorrhages and neo-
vascularization may have severe underlying retinal disease. 
Vitreous hemorrhage may spontaneously resolve without 
any intervention. In patients with retinal tractional diseases 
and repeated vitreous hemorrhages, however, pars plana 
vitrectomy (PPV) should be considered to try to avoid 
further damage. One earlier report suggested that PPV 
had extremely poor outcomes in ABD patients and thus 
should be avoided.127 However, as more advanced vitreo-
retinal surgical techniques and technologies as well as better 
medical therapies become available, recent reports have all 
demonstrated that vitrectomy has a beneficial effect on vision 
in ABD.128–131 In cases of retinal neovascularization, early 
diagnosis and treatment with retinal photocoagulation may be 
beneficial,132 but some investigators believe that this will lead 
to production of retinal antigens which may lead to systemic Clinical Ophthalmology 2009:3 576
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sensitization and thus exacerbation of ABD. In addition, laser 
may not be as effective as certain immunosuppressive agents 
in treating neovascularization. For instance, Tugal-Tutkun’s 
group found that optic disc neovascularization associated 
with ABD was more successfully treated with IFN-α than 
photocoagulation.133
Conclusion
ABD-associated ocular disease remains one of the most 
difficult diseases an ophthalmologist will encounter in his or 
her career. Its relentlessly explosive nature and progressive 
course frequently cause blindness without much warning. 
Therefore, it is imperative for a clinician to diagnose the 
disease early and institute aggressive therapy if necessary. 
While there are a number of treatment options available, none 
is definitively effective or safe. Care and expertise are needed 
in the selection and administration of immunomodulatory 
regimens, and this will likely require a coordinated effort 
between the ophthalmologist and a chemotherapist. When one 
faces an especially difficult case, timely referral to a specialist 
in ocular inflammatory disease and immunology is essential.
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